NRIX (Nurix Therapeutics, Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by NRIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Gwenn Hansen | Chief Scientific Officer | Sell | — | — |
| 2026-08-05 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | — |
| 2026-08-04 | Hans van Houte | Chief Financial Officer | Sell | — | — |
| 2026-08-03 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-07-30 | Hans van Houte | Chief Financial Officer | MIXED | — | — |
| 2026-07-30 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-07-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | — |
| 2026-07-02 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-06-25 | Gwenn Hansen | Chief Scientific Officer | Sell | — | — |
| 2026-06-25 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-06-02 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-05-15 | ROGER D DANSEY | Director | A | — | — |
| 2026-05-15 | Anil Kapur | Director | A | — | — |
| 2026-05-15 | David L. Lacey | Director | A | — | — |
| 2026-05-15 | Judith A Reinsdorf | Director | A | — | — |
| 2026-05-15 | Edward C Saltzman | Director | A | — | — |
| 2026-05-15 | Paul M Silva | Director | A | — | — |
| 2026-05-15 | Roy D. Baynes | Director | A | — | — |
| 2026-05-15 | JULIA P GREGORY | Director | A | — | — |
| 2026-05-05 | Hans van Houte | Chief Financial Officer | Sell | — | — |
| 2026-05-04 | Christine Ring | Chief Legal Officer | Sell | — | — |
| 2026-05-01 | Christine Ring | Chief Legal Officer | Sell | — | — |
| 2026-04-02 | Christine Ring | Chief Legal Officer | Sell | — | — |
| 2026-03-02 | Christine Ring | Chief Legal Officer | Sell | — | — |
| 2026-02-10 | Gwenn Hansen | Chief Scientific Officer | A | — | — |
| 2026-02-10 | ARTHUR T SANDS | President, CEO | A | — | — |
| 2026-02-10 | Christine Ring | Chief Legal Officer | A | — | — |
| 2026-02-10 | Hans van Houte | Chief Financial Officer | A | — | — |
| 2026-02-09 | Christine Ring | Chief Legal Officer | Sell | — | — |
| 2026-02-03 | Gwenn Hansen | Chief Scientific Officer | M | — | — |
| 2026-01-30 | Hans van Houte | Chief Financial Officer | MIXED | — | — |
| 2026-01-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | — |
| 2026-01-30 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2026-01-20 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2025-12-18 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2025-11-24 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2025-11-10 | ROGER D DANSEY | Director | A | — | — |
| 2025-11-03 | Hans van Houte | Chief Financial Officer | Sell | — | — |
| 2025-10-30 | Hans van Houte | Chief Financial Officer | MIXED | — | — |
| 2025-10-30 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2025-10-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | — |
| 2025-10-23 | Gwenn Hansen | Chief Scientific Officer | A | — | — |
| 2025-09-17 | JULIA P GREGORY | Director | M | — | — |
| 2025-08-01 | Hans van Houte | Chief Financial Officer | Sell | — | — |
| 2025-07-30 | Hans van Houte | Chief Financial Officer | MIXED | — | — |
| 2025-07-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | — |
| 2025-07-30 | Christine Ring | Chief Legal Officer | MIXED | — | — |
| 2025-05-19 | David L. Lacey | Director | A | — | — |
| 2025-05-19 | Anil Kapur | Director | A | — | — |
| 2025-05-19 | Lori Anne Kunkel | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,553,898 | — |
| — | 10%+ Owner | 3,500,667 | — |
| — | 10%+ Owner | 2,080,607 | — |
| — | 10%+ Owner | 1,989,000 | — |
| — | 10%+ Owner | 1,533,716 | — |
| — | 10%+ Owner | 1,176,470 | — |
| — | 10%+ Owner | 875,000 | — |
| — | 10%+ Owner | 784,313 | — |
| — | 10%+ Owner | 686,274 | — |
| — | Director | 124,999 | — |
| — | Chief Scientific Officer | 121,583 | — |
| — | Chief Business Officer | 120,996 | — |
| — | Chief Financial Officer | 40,166 | — |
| — | Director | 10,750 | — |
| — | Chief Legal Officer | 9,110 | — |
| — | EVP and COO | 6,455 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NRIX quote page; the site-wide leaderboard is on the insider transactions hub.